Patents by Inventor Frank Hennecke
Frank Hennecke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230416296Abstract: This invention relates to methods for oligonucleotide synthesis, specifically the synthesis of oligonucleotides that contain a high content of guanine monomers. In more detail, the invention relates to a method for coupling a nucleoside phosphor amidite during the synthesis of an oligonucleotide to a universal support, to a first nucleoside, or to an extending oligonucleotide.Type: ApplicationFiled: September 15, 2022Publication date: December 28, 2023Inventors: Frank HENNECKE, Matthias KINZLER, Philippe SAUDAN, Jennifer ERICKSON, Isabelle LACAN, Chi LAN LE
-
Publication number: 20220089648Abstract: This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.Type: ApplicationFiled: April 13, 2021Publication date: March 24, 2022Inventors: Marcel EMMERLING, Frank HENNECKE, Holger PFRÜNDER, Martin RHIEL, Philipp STEINER
-
Publication number: 20210261958Abstract: The present invention relates to processes for producing compositions comprising (i) a virus-like particle of an RNA bacteriophage, and (ii) aggregated oligonucleotides, wherein said aggregated oligonucleotides are packaged into said virus-like particle. The invention further provides processes for producing nucleotide compositions comprising aggregated oligonucleotides suitable for use in the aforementioned processes before. Moreover, the invention further provides nucleotide compositions comprising aggregated oligonucleotides. Furthermore, the invention further provides compositions comprising (i) a virus-like particle of an RNA bacteriophage, and (ii) aggregated oligonucleotides, wherein said aggregated oligonucleotides are packaged into said virus-like particle.Type: ApplicationFiled: April 8, 2019Publication date: August 26, 2021Applicant: CheckMate PharmaCeuticalsInventors: Evan David WALTERS, Frank HENNECKE
-
Publication number: 20200223891Abstract: This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.Type: ApplicationFiled: October 16, 2019Publication date: July 16, 2020Inventors: Marcel EMMERLING, Frank HENNECKE, Holger PFRÜNDER, Martin RHIEL, Philipp STEINER
-
Publication number: 20180194795Abstract: This invention relates to methods for oligonucleotide synthesis, specifically the synthesis of oligonucleotides that contain a high content of guanine monomers. In more detail, the invention relates to a method for coupling a nucleoside phosphoramidite during the synthesis of an oligonucleotide to a universal support, to a first nucleoside, or to an extending oligonucleotide.Type: ApplicationFiled: July 6, 2016Publication date: July 12, 2018Inventors: Frank HENNECKE, Matthias KINZLER, Philippe SAUDAN, Jennifer ERICKSON, Isabelle LACAN, Chi LAN LE
-
Publication number: 20170305972Abstract: This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.Type: ApplicationFiled: November 17, 2016Publication date: October 26, 2017Inventors: Marcel EMMERLING, Frank HENNECKE, Holger PFRÜNDER, Martin RHIEL, Philipp STEINER
-
Patent number: 9518095Abstract: This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.Type: GrantFiled: April 7, 2014Date of Patent: December 13, 2016Assignee: KUROS BIOSCIENCES AGInventors: Marcel Emmerling, Frank Hennecke, Holger Pfründer, Martin Rhiel, Philipp Steiner
-
Publication number: 20150104827Abstract: This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.Type: ApplicationFiled: April 7, 2014Publication date: April 16, 2015Applicant: CYTOS BIOTECHNOLOGY AGInventors: MARCEL EMMERLING, Frank Hennecke, Holger Pfründer, Martin Rhiel, Philipp Steiner
-
Publication number: 20120322103Abstract: This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.Type: ApplicationFiled: December 22, 2011Publication date: December 20, 2012Applicant: Cytos Biotechnology AGInventors: Marcel EMMERLING, Frank Hennecke, Holger Pfründer, Martin Rhiel, Philipp Steiner
-
Publication number: 20110008831Abstract: This invention provides a robust fermentation process for the expression of a capsid protein of a bacteriophage which is forming a VLP by self-assembly, wherein the process is scalable to a commercial production scale and wherein the expression rate of the capsid protein is controlled to obtain improved yield of soluble capsid protein. This is achieved by combining the advantages of fed-batch culture and of lactose induced expression systems with specific process parameters providing improved repression of the promoter during the growth phase and high plasmid retention throughout the process.Type: ApplicationFiled: May 24, 2006Publication date: January 13, 2011Applicant: Cytos Biotechnology AGInventors: Marcel Emmerling, Frank Hennecke, Holger Pfründer, Martin Rhiel, Philipp Steiner
-
Patent number: 7229624Abstract: The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a virus, virus-like particle, viral capsid particle, phage or recombinant form thereof coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions. In one specific embodiment, a versatile new technology based on a cassette-type system (AlphaVaccine Technology) allows production of antigen coated viral particles. Other specific embodiments allow the production of antigen coated hepatitis B virus-like particles or antigen coated Measles virus-like particles.Type: GrantFiled: December 12, 2003Date of Patent: June 12, 2007Assignee: Cytos Biotechnology AGInventors: Wolfgang A. Renner, Frank Hennecke, Lars Nieba, Martin Bachmann
-
Publication number: 20060222652Abstract: The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a core particle that is coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions.Type: ApplicationFiled: November 10, 2005Publication date: October 5, 2006Applicant: Cytos Biotechnology AGInventors: Peter Sebbel, Nicolas Dunant, Martin Bachmann, Alain Tissot, Franziska Lechner, Wolfgang Renner, Frank Hennecke, Lars Nieba
-
Patent number: 6964769Abstract: The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a core particle that is coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions.Type: GrantFiled: May 4, 2001Date of Patent: November 15, 2005Assignee: Cytos Biotechnology AGInventors: Peter Sebbel, Nicolas Dunant, Martin Bachmann, Alain Tissot, Franziska Lechner, Wolfgang A. Renner, Frank Hennecke, Lars Nieba
-
Publication number: 20040136962Abstract: The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a virus, virus-like particle, viral capsid particle, phage or recombinant form thereof coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions. In one specific embodiment, a versatile new technology based on a cassette-type system (AlphaVaccine Technology) allows production of antigen coated viral particles. Other specific embodiments allow the production of antigen coated hepatitis B virus-like particles or antigen coated Measles virus-like particles.Type: ApplicationFiled: December 12, 2003Publication date: July 15, 2004Inventors: Wolfgang A. Renner, Frank Hennecke, Lars Nieba, Martin Bachmann
-
Patent number: 6576443Abstract: The present invention relates to methods for the modification of genomes of eukaryotic cells to alter the expression of endogenous genes. The invention also relates to recombinant eukaryotic host cells and polypeptides produced by the practice of the disclosed methods. The invention further relates to vector systems useful for modifying the genomes of eukaryotic cells to alter the expression of endogenous genes.Type: GrantFiled: December 11, 2000Date of Patent: June 10, 2003Assignee: Cytos Biotechnology AGInventors: Frank Hennecke, Wolfgang A. Renner
-
Publication number: 20030054010Abstract: The invention provides compositions and processes for the production of ordered and repetitive antigen or antigenic determinant arrays. The compositions of the invention are useful for the production of vaccines for the prevention of infectious diseases, the treatment of allergies and the treatment of cancers. Various embodiments of the invention provide for a core particle that is coated with any desired antigen in a highly ordered and repetitive fashion as the result of specific interactions.Type: ApplicationFiled: May 4, 2001Publication date: March 20, 2003Applicant: Cytos Biotechnology AGInventors: Peter Sebbel, Nicolas Dunant, Martin Bachmann, Alain Tissot, Franziska Lechner, Wolfgang A. Renner, Frank Hennecke, Lars Nieba
-
Publication number: 20020168709Abstract: The present invention relates to methods for the modification of genomes of eukaryotic cells to alter the expression of endogenous genes. The invention also relates to recombinant eukaryotic host cells and polypeptides produced by the practice of the disclosed methods. The invention further relates to vector systems useful for modifying the genomes of eukaryotic cells to alter the expression of endogenous genes.Type: ApplicationFiled: December 11, 2000Publication date: November 14, 2002Inventors: Frank Hennecke, Wolfgang A. Renner
-
Patent number: 5882924Abstract: The invention relates to a process for the genetic selection in microorganisms of proteins which are capable of ligand binding, in which process a protein which is capable of ligand binding is presented extracytoplasmically and the signal of the ligand binding is passed on by signal transduction to the biosynthetic machinery of the micoorganism for the purpose of expressing a detectable and/or selectable function. In addition to this, the patent discloses microorganisms which are suitable for use in this process, as well as replicons and processes for their preparation.Type: GrantFiled: October 22, 1997Date of Patent: March 16, 1999Assignee: Behringwerke AktiengesellschaftInventors: Hans-Joachim Fritz, Frank Hennecke, Harald Kolmar